DPS-101 is a novel synergistic combination therapy for topical treatment of plaque psoriasis. It comprises Calcipotriol (calcipotriene; a vitamin D₃ analog) and Nicotinamide (a vitamin B₃ derivative) in a specific ointment formulation.

DPS-101 has two active ingredients that attack psoriasis on two fronts:

(1) An anti-proliferative agent
Calcipotriol is an established anti-proliferative agent with additional anti-inflammatory effects. It acts by binding to the vitamin D receptors expressed in a variety of cell types in the skin including keratinocytes and T-cells. It affects psoriasis by reducing keratinocyte proliferation and through its immunomodulatory effect on T-cells.

(2) An immunoregulatory agent
Nicotinamide is a Th1 immunoregulatory agent, with additional anti-inflammatory and anti-proliferation effects as well.

DPS-101 has successfully completed a large dose-ranging Phase IIb clinical study in chronic plaque psoriasis patients. The study demonstrated that DSP-101 performed substantially better than either of its ingredients, calcipotriol or nicotinamide, alone. DPS-101 has proven to be very safe in all its clinical studies.

A large double blinded, multi-center pivotal Phase III study of DPS-101 is planned in the near future.